Syntheses and structure-activity relationships of 5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2-quinoxaline derivatives with retinoic acid receptor α agonistic activity

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 409-419

  Kikuchi, Kouichi ^a   Hibi, Shigeki ^a   Yoshimura, Hiroyuki ^a   Tokuhara, Naoki ^a   Tai, Kenji ^a   Hida, Takayuki ^a   Yamauchi, Toshihiko ^a   Nagai, Mitsuo ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PYRROLE DERIVATIVE; QUINOXALINE DERIVATIVE; RETINOIC ACID RECEPTOR;

ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; HUMAN; HUMAN CELL; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BENZOIC ACIDS; BINDING, COMPETITIVE; CELL DIFFERENTIATION; CELL LINE; HUMANS; QUINOXALINES; RECEPTORS, RETINOIC ACID; RETINOIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034628481     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990063w     Document Type: Article

References (36)

1. Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. The Retinoid Receptors. The Retinoids: Biology, Chemistry, and Medicine, 2nd ed.; Raven Press: New York, 1994.
2. Leid, M.; Kastner, P.; Chambon, P. Multiplicity Generates Diversity in the Retinoic Acid Signaling Pathways. Trends Biochem. Sci. 1992, 17, 427-433.
3. (a) Orfanos, C. E.; Ehlert, R.; Gollnick, H. The Retinoids. A Review of Their Clinical Pharmacology and Therapeutic Use. Drugs 1987, 34, 459-503.
4. (b) Orfanos, C. E.; Zouboulis, C. C.; Almond-Roesler, B.; Geilen, C. C. Current Use and Future Potential Role of Retinoids in Dermatology [Review]. Drugs 1997, 53, 358-388.
5. (a) Smith, M. A.; Parkinson, D. R.; Cheson, B. D.; Friedman, M. A. Retinoids in Cancer Therapy. J. Clin. Oncol. 1992,10, 839-864.
6. (b) Vokes, E. E.; Weichselbaum, R. R.; Lippman, S. M.; Hong, W. K. Head and Neck Cancer. N. Engl. J. Med. 1993, 328, 184-194.
7. (c) Nagpal, S.; Chandraratna, R. A. S. Retinoids as Anti-Cancer Agents [Review]. Curr. Pharm. Des. 1996, 2, 295-316.
8. (d) Lotan, R. Retinoids in Cancer Chemoprevention. FASEB J. 1996, 10, 1031-1039.
9. (e) Hong, W. K.; Sporn, M. B. Recent Advances in Chemoprevention of Cancer. Science 1997, 278, 1073-1077.
10. (a) Amstrong, R. B.; Ashenfelter, K. O.; Eckhoff, C.; Levin, A. A.; Shapio, S. S. General and Reproductive Toxicology of Retinoids. The Retinoids: Biology, Chemistry, and Medicine, 2nd ed.; Raven Press: New York, 1994; pp 545-572.
11. (b) Standeven, A. M.; Beard, R. L.; Johnson, A. T. Boehm, M. F. Escobar, M.; Heyman, R. A.; Chandraratna, R. A. S. Retinoid-Induced Hypertriglyceridemia in Rats Is Mediated by Retinoic Acid Receptors. Fundam. Appl. Toxicol. 1996, 33, 264-271.
12. (c) Soprano, D. R.; Soprano, K. J. Retinoids as Teratogens [Review]. Annu. Rev. Nutr. 1995, 15, 111-132.
13. (d) Willhite, C. C.; Dawson, M. I. Structure-Activity Relationships of Retinoids in Developmental Toxicology IV. Planar Cisoid Conformational Restriction. Toxicol. Appl. Pharmacol. 1990, 103, 324-344.
14. (a) Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Himi, T.; Shudo, K. Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity. J. Med. Chem. 1988, 31, 2182-2192.
15. (b) Teng, M.; Duong, T. T.; Klein, E. S.; Chandraratna, R. A. S. Identification of a Retinoic Acid Receptor a Subtype Specific Agonist. J. Med. Chem. 1996, 39, 3035-3038.
16. (c) Johnson, A. T.; Klein, E. S.; Wang, L.; Pino, M. E.; Chandraratna, R. A. S. Identification of Retinoic Acid Receptor β Subtype Specific Agonists. J. Med. Chem. 1996, 39, 5027-5030.
17. (d) Esgleyes-Ribot, T.; Chandraratna, R. A. S.; Lew-Kaya, D.; Sefton, J.; Duvic, M. J.; Response of Psoriasis to a New Topical Retinoid, AGN190168. J. Am. Acad. Dermatol. 1994, 30, 581-590.
18. (e) Delescluse, C.; Cavey, M. T.; Martin, B.; Bernard, B. A.; Reichert, U.; Maignan, J.; Darmon, M.; Shroot, B. Selective High Affinity Retinoic Receptor α or β-γ Ligands. Mol. Pharmacol. 1991, 40, 556-562.
19. (f) Charpentier, B.; Bernardon, J.-M.; Eustache, J.; Millois, C.; Martin, B.; Michel, S.; Shroot, B. Synthesis, Structure-Activity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes. J. Med. Chem. 1995, 38, 4993-5006.
20. (g) Yu, K.-L.; Spinazze, P.; Ostrowski, J.; Currier, S. J.; Pack, E. J.; Hammer, L.; Roalsvig, T.; Honeyman, J. A.; Tortolani, D. R.; Reczek, P. R.; Mansuri, M. M.; Starret, J. E., Jr. Retinoic Acid Receptor β, γ-Selective Ligands: Synthesis and Biological Activity of 6-Substituted 2-Naphthoic Acid Retinoids. J. Med. Chem. 1996, 39, 2411-2421.
21. Benbrook, D. M.; Madler, M. M.; Spruce, L. W.; Birckbichler, P. J.; Nelson, E. C.; Subramanian, S.; Weerasekare, G. M.; Gale, J. B.; Patterson, M. K., Jr.; Wang, B.; Wang, W.; Lu, S.; Rowland, T. C.; DiSivestro, P.; Lindamood, C., III; Hill, D. L.; Berlin K. D. Biologically Active Heteroarotinoids Exhibiting Anticancer Activity and Decreased Toxicity. J. Med. Chem. 1997, 40, 3567-3583.
22. Tobita, T.; Takeshita, A.; Kitamura, K.; Ohnishi, K.; Yanagi, M.; Hiraoka, A.; Karasuno, T.; Takeuchi, M.; Miyawaki, S.; Ueda, R.; Naoe, T.; Ohno, R. Treatment With a New Synthetic Retinoid, Am 80, of Acute Promyelocytic Leukemia Relapsed From Complete Remission Induced by All-trans Retinoic Acid. Blood 1997, 90, 967-973.
23. (a) Ishibashi, Y.; Harada, S.; Ohkawara, A.; Tagami, H.; Iizuka, H.; Toda, K.; Takigawa, M.; Shimizu, M.; Nakashima, M. Clinical Phase II Study on Am-80 Ointment-Investigation of Systemic Effect-. Rinshouiyaku 1995, 11, 721-732.
24. (b) Ishibashi, Y. Efficacy of Am-80 Ointment on Psoriasis -A Bilateral-paired Comparative Study with Betamethasone Valerate Ointment (Phase III Study)-. Rinshouiyaku 1995, 11, 733-759.
25. Kuwabara, K.; Shudo, K.; Hori, Y. Novel Synthetic Retinoic Acid Inhibits Rat Collagen Arthritis and Differentially Affects Serum Immunoglobulin Subclass Levels. FEBS Lett. 1996, 378, 153-156.
26. (a) Yoshimura, H.; Nagai, M.; Hibi, S.; Kikuchi, K.; Abe, S.; Hida, T.; Higashi, S.; Hishinuma, I.; Yamanaka, T. A Novel Type of Retinoic Acid Receptor Antagonist: Synthesis and Structure-Activity Relationships of Heterocyclic Ring-Containing Benzoic Acid Derivatives. J. Med. Chem. 1995, 38, 3163-3173.
27. (b) Hibi, S.; Kikuchi, K.; Yoshimura, H.; Nagai, M.; Tai, K.; Hida, T. Syntheses and Structure-Activity Relationships of Novel Retinoid X Receptor Agonists. J. Med. Chem. 1998, 41, 3245-3252.
28. This compound was originally synthesized in our laboratory. A patent application was filed in June 1996 and opened in January 1997. Kikuchi, K.; Tagami, K.; Yoshimura, H.; Hibi, S.; Nagai, M.; Abe, S.; Okita, M.; Hida, T.; Higashi, S.; Tokuhara, N.; Kobayashi, S. Heterocyclic Carboxylic Acid Derivatives and Drugs Containing the Same. WO 97/02244. Recently Dr. P. Jones et al. reported a new route for the synthesis of ER-33635 and described the retinoidal activity of this compound. Jones, P.; Villeneuve, G. B.; Fei, C.; DeMarte, J.; Haggarty, A. J.; Nwe, K. T.; Martin, D. A.; Lebuis, A.-M.; Finkelstein, J. M.; Gour-Salin, B. J.; Chan, T. H.; Leyland-Jones, B. R. Synthesis and Structure-Activity Relationships of 2-Pyrazinylcarboxamidobenzoates and β-Ionylideneacetamidobenzoates with Retinoidal Activity. J. Med. Chem. 1998, 41, 3062-3077.
29. This compound was originally synthesized in our laboratory. A patent application was filed in June 1996 and opened in January 1997. Kikuchi, K.; Tagami, K.; Yoshimura, H.; Hibi, S.; Nagai, M.; Abe, S.; Okita, M.; Hida, T.; Higashi, S.; Tokuhara, N.; Kobayashi, S. Heterocyclic Carboxylic Acid Derivatives and Drugs Containing the Same. WO 97/02244. Recently Dr. P. Jones et al. reported a new route for the synthesis of ER-33635 and described the retinoidal activity of this compound. Jones, P.; Villeneuve, G. B.; Fei, C.; DeMarte, J.; Haggarty, A. J.; Nwe, K. T.; Martin, D. A.; Lebuis, A.-M.; Finkelstein, J. M.; Gour-Salin, B. J.; Chan, T. H.; Leyland-Jones, B. R. Synthesis and Structure-Activity Relationships of 2-Pyrazinylcarboxamidobenzoates and β-Ionylideneacetamidobenzoates with Retinoidal Activity. J. Med. Chem. 1998, 41, 3062-3077.
30. This compound was originally synthesized in our laboratory. A patent application was filed in June 1996 and opened in January 1997. Kikuchi, K.; Tagami, K.; Yoshimura, H.; Hibi, S.; Nagai, M.; Abe, S.; Okita, M.; Hida, T.; Higashi, S.; Tokuhara, N.; Kobayashi, S. Heterocyclic Carboxylic Acid Derivatives and Drugs Containing the Same. WO 97/02244. Recently Dr. P. Jones et al. reported a new route for the synthesis of ER-33635 and described the retinoidal activity of this compound. Jones, P.; Villeneuve, G. B.; Fei, C.; DeMarte, J.; Haggarty, A. J.; Nwe, K. T.; Martin, D. A.; Lebuis, A.-M.; Finkelstein, J. M.; Gour-Salin, B. J.; Chan, T. H.; Leyland-Jones, B. R. Synthesis and Structure-Activity Relationships of 2-Pyrazinylcarboxamidobenzoates and β-Ionylideneacetamidobenzoates with Retinoidal Activity. J. Med. Chem. 1998, 41, 3062-3077.
31. The methyl benzoate of this compound was reported by a BASF group. Wuest, H.-H.; Janssen, B.; Murray, W. V.; Wachter, M. P.; Bell, S. (BASF A.-G.). Diarylsubstituierte Heterocyclische Werbindung, Ihre Herstellung Und Arzneimittel Und Kosmetika Daraus. (New Diaryl Heterocyclic Compounds, Useful as Retinoid Medicaments.) European Patent Application EP0382077A, 1990.
32. Groot, A. A.; Wynberg, H. The Synthesis of o-Di-t-butyl Heteroaromatic Compounds. J. Org. Chem. 1996, 31, 3954-3958.
33. Steter, H. Catalyzed Addition of Aldehydes to Activated Double Bonds- A New Synthetic Approach, Angew. Chem., Int. Ed. Engl. 1976, 15, 639-647.
34. Boehm, M. F.; Zhang, L.; Zhi, L.; McClung, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nadzan, A. M. Design and Synthesis of Potent Retinoid X Receptor Selective Ligands that Induce Apoptosis in Leukemia Cells. J. Med. Chem. 1995, 38, 3146-3155.
35. Dawson, M.; Hobbs, P. D.; Derdzinski, Chao, W.-R.; Frenking, G.; Loew, G. H.; Jetten, A. M.; Napoli, J. L.; Williams, J. B.; Sani, B. P.; Wille, J. J.; Schiff, L. J. Effect of Structural Modifications in the C7-C11 Region of the Retinoid Skeleton on Biological Activity in a Series of Aromatic Retinoids. J. Med. Chem. 1989, 32, 1504-1517.
36. Goto, M.; Yamada, K.; Katayama, K.; Tanaka, I. Inhibitory Effect of E3330, a Novel Quinone Derivative able to Suppress Tumor Necrosis Factor-α Generation, on Activation of Nuclear Facter-κB. Mol. Pharmacol. 1996, 49, 860-873.